The U.S. Food and Drug Administration (FDA) recently conducted a surveillance Good Laboratory Practice (GLP) inspection of WuXi’s toxicology facility in Suzhou, and the facility passed with no major observations. The inspection was extensive, lasting five days and included the review of numerous processes and the audit of four studies.
The outcome of the FDA inspection — following excellent results of earlier OECD and CFDA inspections — further demonstrates the consistency of WuXi’s GLP compliance and the quality of our services.
WuXi has completed 92 IND-enabling programs for global submissions during the toxicology facility’s five years of operation.
See official press release here.
WuXi’s Toxicology Facility in Suzhou Passes OECD GLP Inspection